Page 4 - Eric Schoen News Today

AUSTIN, Texas, Nov. 22, 2022 -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced... | November 22, 2022

Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll52-week Study of Simufilam 100 mgUp to 1,600 Patients...

Cassava Sciences, Inc. SAVA, a clinical-stage biotechnology company focused on Alzheimers disease, was recently informed by the Journal of Prevention of

SAVA stock is rising on hopes of a buyout, which could also mean optimism for its Alzheimer's test and proposed treatment.

- In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media...

27.07.2022 - - In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures. - No government agency has informed Cassava ...

On Tuesday a case was filed in the Western District of Texas by Manhoar Rao, as a proposed class action, against Cassava Sciences Inc., Remo Barbier, and

Cassava Sciences Announces Conference Call for Second Quarter Financial Results - Call-in on Tuesday, August 3rd at 9 a.m. ET - August 02, 2021 19:54 ET | Source: Cassava Sciences, Inc. Cassava Sciences, Inc. Austin, Texas, UNITED STATES AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on...

(512) 501-2450 The content of this press release is solely the responsibility of Cassava Sciences and does not necessarily represent the official views of the NIH. Cautionary Note Regarding Forward-Looking Statements: This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our strategy and plans; the treatment of Alzheimer’s disease; the status of current an...

Published: May 10, 2021 AUSTIN, Texas, May 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences Inc., (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer’s disease. Simufilam is a drug candidate that seeks to reduce neurodegeneration and neuroinflammation. Cassava Sciences believes the ability to impact more than one aspect of Alzheimer’s d...